Drugs in ATC Class S01EB

Up to Top Level ATC Classes

Up to S - Sensory organs

Up to S01 - OPHTHALMOLOGICALS

Up to S01E - ANTIGLAUCOMA PREPARATIONS AND MIOTICS

Drugs in ATC Class: S01EB - Parasympathomimetics

Tradename	Generic Name
BETOPTIC PILO	betaxolol hydrochloride; pilocarpine hydrochloride
OCUSERT PILO-20	pilocarpine
OCUSERT PILO-40	pilocarpine
PILOPINE HS	pilocarpine hydrochloride
ISOPTO CARPINE	pilocarpine hydrochloride
PILOCARPINE HYDROCHLORIDE	pilocarpine hydrochloride

Parasympathomimetics Market and Patent Landscape Analysis (ATC S01EB)

Last updated: February 19, 2026

Executive Summary

The global market for parasympathomimetics, classified under ATC code S01EB for topical use in ophthalmology, is characterized by established therapeutic uses primarily for glaucoma management. Patent activity in this sector focuses on novel formulations, delivery systems, and combinations with other therapeutic agents to improve efficacy, reduce side effects, and enhance patient compliance. Key patent filings indicate ongoing research into extended-release mechanisms and targeted drug delivery.

What is the scope of ATC Class S01EB?

ATC Class S01EB encompasses drugs used topically in ophthalmology that act as parasympathomimetics. These agents stimulate the parasympathetic nervous system, specifically the oculomotor nerve, leading to miosis (pupil constriction) and ciliary muscle contraction. This mechanism reduces intraocular pressure (IOP) by increasing aqueous humor outflow through the trabecular meshwork.

The primary therapeutic indication for S01EB drugs is the management of glaucoma and ocular hypertension. These conditions are characterized by elevated IOP, which can damage the optic nerve and lead to irreversible vision loss.

Key drugs within this classification include:

• Pilocarpine: A direct-acting cholinergic agonist, it is one of the oldest and most well-known parasympathomimetics used in ophthalmology.
• Carbachol: Another cholinergic agonist with both muscarinic and nicotinic receptor activity, although its ophthalmological use is primarily through its muscarinic effects.

While effective, the use of direct parasympathomimetics like pilocarpine can be associated with significant side effects, including brow ache, miosis, blurred vision, and accommodative spasm, which can limit patient tolerance and adherence.

What are the principal mechanisms of action and therapeutic targets?

Parasympathomimetics in S01EB primarily target muscarinic acetylcholine receptors (mAChRs) in the eye. These receptors are G protein-coupled receptors found in various ocular tissues, including the ciliary muscle, iris sphincter, and conjunctiva.

The key physiological effects leading to IOP reduction are:

1. Miosis: Stimulation of muscarinic receptors on the iris sphincter muscles causes pupillary constriction. This narrows the iris root, which can indirectly influence aqueous outflow.
2. Cycloplegia/Ciliary Muscle Contraction: Activation of muscarinic receptors on the ciliary muscle leads to contraction. This contraction pulls the scleral spur anteriorly and laterally, opening the trabecular meshwork spaces and increasing the facility of aqueous humor outflow.

The therapeutic target is the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma, angle-closure glaucoma (in specific phases), and ocular hypertension. By facilitating aqueous humor drainage, these agents lower IOP, thereby mitigating the risk of optic nerve damage.

What is the current market size and growth trajectory for S01EB parasympathomimetics?

The market for topical parasympathomimetics (S01EB) is relatively mature. While historically significant, their market share has been increasingly influenced by newer classes of glaucoma medications such as prostaglandin analogs, beta-blockers, alpha-adrenergic agonists, and carbonic anhydrase inhibitors, which often offer more favorable tolerability profiles and once-daily dosing.

Accurate, granular market data specifically for the S01EB subclass is challenging to isolate from broader glaucoma medication market reports. However, industry analyses indicate that the overall glaucoma drug market is projected to grow, driven by an aging global population and the increasing prevalence of glaucoma [1]. Within this broader market, S01EB agents represent a smaller, albeit still relevant, segment.

Estimates suggest the global glaucoma drug market was valued at approximately USD 5.0 billion in 2022 and is anticipated to reach USD 6.5 billion by 2028, growing at a CAGR of around 4.3% [2]. The S01EB segment's growth is likely to be slower than the overall market, potentially experiencing modest growth or even a slight decline in some developed markets due to competition, while potentially seeing stable demand in regions where cost-effectiveness remains a primary driver.

Factors influencing market dynamics include:

• Prevalence of Glaucoma: Increasing incidence due to an aging population.
• Competition: Availability of multiple drug classes with varied mechanisms and side effect profiles.
• Patient Compliance: Dosing frequency and tolerability of side effects are critical.
• Genericization: Many established S01EB drugs, such as pilocarpine, are off-patent, leading to price competition.
• Emerging Markets: Potential for stable or growing demand in regions with limited access to newer, more expensive therapies.

What are the key patent trends and competitive intellectual property strategies?

Patent activity surrounding S01EB parasympathomimetics has shifted from foundational compound patents to focus on formulation, delivery systems, and combination therapies. The original patents for pilocarpine and carbachol have long expired, making the market for these individual active pharmaceutical ingredients (APIs) largely generic.

Current patent filings by pharmaceutical companies and research institutions in this space aim to:

1. Improve Drug Delivery and Retention:

   • Extended-Release Formulations: Developing ocular inserts, gels, or sustained-release solutions to reduce dosing frequency and improve patient compliance. Examples include ocular implants or microparticle systems designed to release the drug over days or weeks.
   • Enhanced Penetration: Creating formulations that improve the penetration of the drug through the cornea to reach ocular tissues more effectively.

2. Mitigate Side Effects:

   • Combination Therapies: Patents often cover fixed-dose combinations of parasympathomimetics with other IOP-lowering agents (e.g., prostaglandin analogs, beta-blockers) to achieve synergistic effects and potentially reduce the required dose of individual components, thereby minimizing side effects.
   • Prodrugs and Analogs: Research into modified versions of existing parasympathomimetics that may have a more favorable pharmacokinetic profile or reduced off-target effects.

3. Novel Formulations and Manufacturing Processes:

   • Patents may protect specific excipients, stabilizers, or manufacturing methods that enhance the stability, solubility, or efficacy of existing parasympathomimetic drugs.

Key Players and Patent Filings:

Major pharmaceutical companies with a history in ophthalmology, as well as smaller biotech firms and academic institutions, are active in patenting. Identifying specific patent filers requires detailed database analysis. However, companies known for their ophthalmology portfolios, such as Novartis, Alcon, and Allergan (now part of AbbVie), have historically invested in glaucoma treatments and may hold relevant patents in formulation or combination therapies.

Example Patent Areas:

• WO2018195493A1: Describes an ocular drug delivery device for sustained release of pilocarpine [3]. This type of patent aims to address the short duration of action and frequent dosing associated with conventional pilocarpine eye drops.
• US9878007B2: Covers ophthalmic compositions comprising a cholinergic agonist (like pilocarpine) and an excipient for enhancing ocular drug delivery [4]. Such patents focus on improving the efficacy and comfort of topical administration.
• US20170049566A1: Details a method of treating glaucoma using a combination of a muscarinic agonist and a Rho-kinase inhibitor [5]. This represents a trend towards combining different pharmacological mechanisms to achieve superior IOP reduction.

The patent landscape for S01EB is characterized by incremental innovation focused on overcoming the limitations of older drugs, rather than discovery of entirely new classes of parasympathomimetics.

What are the major manufacturing and supply chain considerations?

Manufacturing of S01EB parasympathomimetics, particularly pilocarpine and carbachol, involves standard pharmaceutical synthesis and formulation processes. Given the long history of these compounds, manufacturing processes are well-established and have been optimized for cost-effectiveness.

Key Manufacturing Aspects:

• API Production: The synthesis of pilocarpine and carbachol involves multi-step organic chemistry. Companies producing these APIs must adhere to Good Manufacturing Practices (GMP) and ensure high purity standards.
• Formulation: The transformation of APIs into ophthalmic solutions, gels, or inserts requires sterile manufacturing environments. This includes:
  • Sterilization: Ophthalmic preparations must be sterile to prevent infection. Methods like terminal sterilization (autoclaving) or aseptic processing are employed.
  • Excipients: Formulations include buffering agents, preservatives (if multi-dose), tonicity adjusters, and viscosity enhancers. The selection and quality of these excipients are critical for stability and tolerability.
  • Packaging: Eye drops are typically packaged in small, sterile plastic bottles with specialized droppers. Extended-release inserts require specialized materials and manufacturing techniques.

Supply Chain Considerations:

• Raw Material Sourcing: Sourcing of chemical precursors for API synthesis must be reliable and compliant with quality standards.
• Global Manufacturing: API manufacturing may be concentrated in specific regions (e.g., China, India) due to cost advantages, while formulation and packaging may occur closer to end markets.
• Regulatory Compliance: All manufacturing facilities and processes must comply with stringent regulations from bodies like the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and other national health authorities.
• Quality Control: Robust quality control measures are essential at every stage of manufacturing and supply chain to ensure product safety, efficacy, and consistency.
• Logistics: Maintaining the integrity of sterile ophthalmic products during transport and storage requires controlled temperature and handling conditions.

Challenges:

• Sterility Assurance: Maintaining sterility throughout the manufacturing and distribution process is paramount and technically demanding.
• Cost Pressures: With many S01EB drugs being off-patent, there is significant price pressure, requiring highly efficient and cost-effective manufacturing.
• Specialized Formulations: Development and manufacturing of advanced delivery systems (e.g., implants, sustained-release gels) require specialized expertise and equipment, posing higher capital investment and operational complexity.

What are the regulatory pathways and challenges for new S01EB related products?

The regulatory pathway for new S01EB-related products depends on whether they represent new chemical entities (NCEs), new formulations of existing APIs, or combination products.

For New Chemical Entities (NCEs) (unlikely for direct parasympathomimetics given market maturity):

• Pre-clinical Studies: Extensive in vitro and in vivo testing to assess pharmacology, pharmacokinetics, toxicology, and efficacy.
• Investigational New Drug (IND) Application: Submission to regulatory authorities (e.g., FDA) to gain approval for human clinical trials.
• Clinical Trials: Phase 1 (safety and pharmacokinetics in healthy volunteers), Phase 2 (efficacy and dose-ranging in patients), and Phase 3 (large-scale efficacy and safety confirmation in target patient populations).
• New Drug Application (NDA) / Marketing Authorisation Application (MAA): Comprehensive submission including all pre-clinical and clinical data, manufacturing information, and proposed labeling for regulatory review and approval.

For New Formulations or Combination Products of Existing APIs (most common scenario for S01EB):

• Abbreviated New Drug Application (ANDA) (for generics): If the new product is a generic version of an approved drug, it must demonstrate bioequivalence to the reference listed drug. For ophthalmic products, demonstrating equivalent bioavailability and equivalent safety and efficacy is critical.
• 505(b)(2) Pathway (U.S. FDA): For new formulations or combinations where some of the underlying data (e.g., safety of the active ingredient) is already available from an approved drug. This pathway can be more efficient than a full NCE submission as it allows reliance on existing FDA findings. This is highly relevant for improved delivery systems or combinations.
• New Combination Product Pathway: For products combining two or more active ingredients, regulatory review may involve multiple agencies or coordinated review, assessing the safety and efficacy of each component and the combination.

Key Regulatory Challenges:

• Demonstrating Bioequivalence/Therapeutic Equivalence: For ophthalmic products, achieving bioequivalence can be complex due to the unique challenges of ocular drug delivery. This requires careful study design and interpretation.
• Ocular Safety and Tolerability: Rigorous assessment of local ocular side effects (e.g., irritation, inflammation, changes in vision) is critical.
• Sterility and Container Closure Integrity: Ensuring that sterile products remain sterile throughout their shelf life and that the packaging system is robust.
• Manufacturing and Quality Control: Meeting stringent GMP requirements for sterile ophthalmic manufacturing.
• Labeling and Prescribing Information: Clearly defining indications, contraindications, warnings, precautions, and adverse reactions based on robust clinical data.
• Post-Market Surveillance: Ongoing monitoring of product performance and safety once it is on the market.

For patents claiming new formulations or delivery systems, the regulatory hurdle primarily lies in demonstrating that the innovation offers a significant clinical benefit, such as improved efficacy, reduced side effects, or enhanced convenience, compared to existing treatments.

Key Takeaways

• The S01EB parasympathomimetic market is mature, with established drugs like pilocarpine primarily used for glaucoma.
• Innovation is focused on formulation improvements, extended-release delivery systems, and combination therapies to enhance tolerability and compliance.
• Patent strategies revolve around novel delivery mechanisms, fixed-dose combinations, and manufacturing process enhancements, rather than new active molecules.
• The overall glaucoma drug market is growing, but S01EB segment growth is expected to be modest due to competition from newer drug classes.
• Manufacturing requires strict adherence to sterile production standards and GMP, with cost-effectiveness being a major driver in the generic segment.
• Regulatory pathways for new S01EB products typically utilize the 505(b)(2) pathway or ANDA process, focusing on demonstrating improved clinical benefits or bioequivalence.

FAQs

1. Are there any new chemical entities in the S01EB class expected to enter the market soon? The development of entirely new chemical entities directly targeting muscarinic receptors for topical ophthalmic use is rare. Current research and patent activity primarily focus on optimizing existing parasympathomimetic compounds through advanced formulations and delivery systems.

2. How do S01EB parasympathomimetics compare in terms of side effect profiles to prostaglandin analogs, another common class of glaucoma medications? Parasympathomimetics like pilocarpine are associated with more frequent local side effects, including miosis (pupil constriction), brow ache, and accommodative spasm (difficulty focusing), which can affect vision quality and patient comfort. Prostaglandin analogs, while potentially causing conjunctival hyperemia, eyelash growth, and iris color changes, often have a more favorable tolerability profile for many patients, allowing for less frequent dosing.

3. What is the primary challenge in developing and manufacturing novel sustained-release formulations for S01EB drugs? The primary challenge lies in achieving a consistent and predictable drug release profile over the intended duration within the challenging environment of the eye, while also ensuring sterility, biocompatibility, and minimizing ocular irritation or foreign body sensation.

4. Can S01EB drugs be used in combination with other glaucoma medications? Yes, S01EB drugs are frequently used in combination therapies with other classes of glaucoma medications to achieve additive or synergistic IOP-lowering effects. Many fixed-dose combination eye drops and combination treatment regimens include a parasympathomimetic alongside agents like beta-blockers, prostaglandin analogs, or carbonic anhydrase inhibitors.

5. What impact does patent expiry have on the market for S01EB parasympathomimetics? Patent expiry for foundational S01EB drugs, such as pilocarpine, leads to significant price erosion due to generic competition. This increases accessibility and affordability but reduces profit margins for manufacturers of the original branded products, driving innovation towards differentiated, patent-protected formulations or combinations.

---

Citations

[1] Global Market Insights. (2023). Glaucoma Drugs Market Size, Share & Industry Analysis Report. [Report Data as cited by various industry news outlets].

[2] Mordor Intelligence. (2023). Glaucoma Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028). [Report Data as cited by various industry news outlets].

[3] WO2018195493A1. (2018). Ocular Drug Delivery Device and Method. World Intellectual Property Organization.

[4] US9878007B2. (2018). Ophthalmic Compositions Containing Cholinergic Agonists and Methods for Enhancing Ocular Drug Delivery. U.S. Patent and Trademark Office.

[5] US20170049566A1. (2017). Method of Treating Glaucoma. U.S. Patent and Trademark Office.